Clinical trials: Urge Incontinence
Overactive Bladder, Urge Incontinence
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI).
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- NCT03556891
- Testing
- eCoin Tibial Nerve Stimulation
- Where
- 15 sites in United States
- Volunteers
- 133 people
- Sponsor
- Valencia Technologies Corporation
Overactive Bladder
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in participants with OAB for up to 52 weeks.
- Trial name
- Empowur (NCT03583372)
- Testing
- Vibegron, Tolterodine Tartrate ER
- Where
- 107 sites in United States
- Volunteers
- 506 people
- Sponsor
- Urovant Sciences GmbH
Urinary Incontinence, Stress
To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms
The purpose of this study is to determine how effective duloxetine is in treating women who are 65 years of age or older with symptoms of stress urinary incontinence, or with a combination of stress urinary incontinence and urge…
- Trial name
- NCT00244296
- Testing
- Duloxetine hydrochloride
- Where
- 31 sites in France, Germany and 5 more
- Volunteers
- 276 people
- Sponsor
- Eli Lilly and Company
Urinary Incontinence
Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence
The purpose of this study is to determine if a new drug treatment is effective for the treatment of symptoms of urinary incontinence.
- Trial name
- NCT01340066
- Testing
- UISH001
- Where
- 3 sites in United States
- Volunteers
- 94 people
- Sponsor
- Beech Tree Labs, Inc.
Urinary Urge Incontinence
InterStim® Amplitude Study
This feasibility study will explore the effects of three different InterStim amplitude settings on overactive bladder symptoms (OAB).
- Trial name
- NCT03335761
- Testing
- InterStim Therapy
- Where
- 18 sites in United States, Belgium and 5 more
- Volunteers
- 97 people
- Sponsor
- MedtronicNeuro
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.
Urinary Incontinence, Urge
Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt
The ARTISAN-SNM study is designed to evaluate the safety and effectiveness of the Axonics Sacral Neuromodulation System as an aid in the treatment of the symptoms of urinary urgency incontinence (UUI) in patients who have failed…
- Trial name
- ARTISAN-SNM (NCT03327948)
- Testing
- Axonics Sacral Neuromodulation System (SNM) System
- Where
- 4 sites in United States, Netherlands and 1 more
- Volunteers
- 129 people
- Sponsor
- Axonics, Inc.
Urinary Incontinence
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
This is a placebo-controlled, double-blind study to evaluate the safety and efficacy of two doses of DR-3001 in women with overactive bladder who have symptoms of predominant or pure urge incontinence, urinary urgency and…
- Trial name
- NCT00196404
- Testing
- DR-3001a, DR-3001b
- Where
- 48 sites in United States, Canada
- Volunteers
- 800 people
- Sponsor
- Duramed Research
Urinary Bladder, Overactive
A Study to Compare the Effectiveness and Safety of Fesoterodine and Placebo in an Elderly Population of Patients Who go to the Toilet Very Frequently Due to Overactive Bladder.
The drug being studied, fesoterodine fumarate helps prevent the bladder neck opening at unwanted times and has been shown to help patients with overactive bladder syndrome pass urine less frequently than before treatment.
- Trial name
- SOFIA (NCT00798434)
- Testing
- Fesoterodine fumarate
- Where
- 60 sites in Austria, Belgium and 13 more
- Volunteers
- 794 people
- Sponsor
- Pfizer
Incontinence, Urge
T-DOC® 5 Fr Pediatric Clinical Investigation
A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects
- Trial name
- NCT03429270
- Testing
- TDOC 5Fr
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Laborie Medical Technologies Inc.
Overactive Bladder
Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.
Objective of this study was confirmation on non-inferiority and validation of similar safety profile of new anti-muscarinic medicinal product Uritos® (Imidafenacin) in comparison with other product from m-cholinergic antagonists…
- Trial name
- NCT03575702
- Testing
- Uritos®, Urotol®
- Where
- 11 sites in Russia
- Volunteers
- 300 people
- Sponsor
- R-Pharm
Urinary Bladder, Overactive
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
- Trial name
- ARIES (NCT00662909)
- Testing
- Mirabegron
- Where
- 125 sites in United States, Canada
- Volunteers
- 2,149 people
- Sponsor
- Astellas Pharma Inc
Urinary Incontinence
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
This study is designed to investigate the efficacy and safety of treatment of overactive bladder with darifenacin administered alone or in conjunction with behavioral modification therapies.
- Trial name
- NCT00127270
- Testing
- Darifenacin, Behavioral therapy
- Where
- 67 sites in United States
- Volunteers
- 395 people
- Sponsor
- Novartis
Urinary Urge Incontinence
Study of 30-Minute Stimulation With the Neuspera Sacral Neuromodulation (SNM) System
Single-arm study conducted in participants for the treatment of urinary urge incontinence in patients who have failed, could not tolerate, or were not a candidate for more conservative treatments.
- Trial name
- NCT07247136
- Testing
- Neuspera Implantable Sacral Neuromodulation System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Neuspera Medical, Inc.
Urge Incontinence, Overactive Bladder (OAB)
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
The purpose of this study was to evaluate the efficacy of mirabegron for the treatment of overactive bladder (OAB) in Chinese participants.
- Trial name
- NCT04562090
- Testing
- mirabegron
- Where
- 15 sites in China
- Volunteers
- 249 people
- Sponsor
- Astellas Pharma China, Inc.
Urinary Incontinence, Stress
Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.
The purpose of the study is to evaluate the effectiveness of duloxetine in reducing urinary incontinence(leakage of urine)occurrences in women due to physical stress and leakage that occurs during a strong need(urge) to urinate.
- Trial name
- NCT00190814
- Testing
- duloxetine
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Eli Lilly and Company
Overactive Bladder
SSR240600C Treatment in Women With Overactive Bladder
The primary objective of this study is to evaluate the efficacy of SSR240600C in women with overactive bladder compared to placebo using tolterodine as a study calibrator.
- Trial name
- BILADY (NCT00564226)
- Testing
- SSR240600C, tolterodine
- Where
- 7 sites in United States, Canada and 5 more
- Volunteers
- 345 people
- Sponsor
- Sanofi
Overactive Bladder, Urge Incontinence
AURA 1: Augmenting Urinary Reflex Activity: Study 1
AURA 1 (Augmenting Urinary Reflex Activity: study 1) is a study that evaluates the electrophysiological responses of pudendal nerve stimulation using short-duration extracorporeal stimulation
- Trial name
- AURA1 (NCT05256498)
- Testing
- Picostim Amber
- Sponsor
- Amber Therapeutics Ltd
Urinary Urge Incontinence
InterStim® Sacral Nerve Modulation Cycling Study
The study will assess the effects of different InterStim cycling settings on urinary urge incontinence.
- Trial name
- NCT01957137
- Testing
- InterStim® (Device Programming)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- MedtronicNeuro
Urinary Bladder, Overactive
Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of YM178 against placebo and tolterodine to treat patients with symptoms of over active bladder.
- Trial name
- Blossom (NCT01604928)
- Testing
- YM178, tolterodine
- Where
- 30 sites in Belgium, Czechia and 4 more
- Volunteers
- 260 people
- Sponsor
- Astellas Pharma Europe B.V.